Mohammad Reza Safarinejad1. 1. Urology and Nephrology Research Center, Shahid Beheshti University (MS), Teheran, Iran. safarinejad@urologist.md
Abstract
PURPOSE: We determined the safety and efficacy of sorafenib in patients with castrate resistant prostate cancer (CRPC). METHODS: Sixty-four chemotherapy and radiotherapy naïve patients with CRPC received 400 mg sorafenib orally twice daily in 6-week cycles. All patients had bone metastasis, while 16 had lymph node-, 9 had liver-, and 10 had lung metastases. Treatment was continued until disease progression or excessive toxicity. RESULTS: All patients were assessable for response. A median of 6.4 consecutive cycles was administered per patient. Median overall survival for all patients was 14.6 months (confidence interval [CI], 8.2-22.2). No complete response (CR) occurred. Of the 35 patients with measurable extraosseous disease, 7 (20%) had a partial response. Overall, 13 patients (20.3%; 95% CI, 4%-32%) achieved a 50% or greater reduction (partial response [PR]) in prostate-specific antigen (PSA) level after two cycles. The median response duration was 2.5 months (95% CI, 1.4 to 4.8), and the median time to progression was 5.9 months (95% CI 3.6 to 7.6). There was no treatment-related death. Toxicities were well tolerated. CONCLUSIONS: Sorafenib demonstrated some antitumor activity. Further studies are necessary to determine a subgroup of patients who would likely respond better to sorafenib. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: We determined the safety and efficacy of sorafenib in patients with castrate resistant prostate cancer (CRPC). METHODS: Sixty-four chemotherapy and radiotherapy naïve patients with CRPC received 400 mg sorafenib orally twice daily in 6-week cycles. All patients had bone metastasis, while 16 had lymph node-, 9 had liver-, and 10 had lung metastases. Treatment was continued until disease progression or excessive toxicity. RESULTS: All patients were assessable for response. A median of 6.4 consecutive cycles was administered per patient. Median overall survival for all patients was 14.6 months (confidence interval [CI], 8.2-22.2). No complete response (CR) occurred. Of the 35 patients with measurable extraosseous disease, 7 (20%) had a partial response. Overall, 13 patients (20.3%; 95% CI, 4%-32%) achieved a 50% or greater reduction (partial response [PR]) in prostate-specific antigen (PSA) level after two cycles. The median response duration was 2.5 months (95% CI, 1.4 to 4.8), and the median time to progression was 5.9 months (95% CI 3.6 to 7.6). There was no treatment-related death. Toxicities were well tolerated. CONCLUSIONS:Sorafenib demonstrated some antitumor activity. Further studies are necessary to determine a subgroup of patients who would likely respond better to sorafenib. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: C Nabhan; D Villines; T V Valdez; K Tolzien; T M Lestingi; J D Bitran; S M Christner; M J Egorin; J H Beumer Journal: Br J Cancer Date: 2012-07-17 Impact factor: 7.640
Authors: Friedemann Zengerling; Wolfgang Streicher; Andres J Schrader; Mark Schrader; Bianca Nitzsche; Marcus V Cronauer; Michael Höpfner Journal: Int J Mol Sci Date: 2012-09-14 Impact factor: 6.208